3D Systems Corporation, in collaboration with French MedTech company TISSIUM, has achieved a significant milestone with the FDA's De Novo marketing authorization for their innovative 3D-printed medical device aimed at regenerative repair of peripheral nerve damage. This first-of-its-kind, bioabsorbable device, known as COAPTIUM® CONNECT with TISSIUM Light, leverages TISSIUM's proprietary biomorphic programmable polymers and 3D Systems' advanced bioprinting technologies. The approval marks a transformative step in patient care, offering a sutureless, atraumatic solution for nerve repair. This achievement underscores the partnership's success in pioneering regenerative medical solutions and sets a new industry standard for high-resolution elastomeric medical implants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.